The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study,” published in the March 2025 issue of Journal of the ...

The US regulator has cleared Lymphir (denileukin diftitox) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, resurrecting the ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

Foss et al, Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma, Journal of ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Lacutamab previously received a Fast Track designation by the FDA in 2019 for the treatment of adult patients with relapsed or refractory Sézary syndrome who have received at least two prior ...

The study included patients who were heavily pre-treated, some of whom had received prior CAR-T therapy ... for adults with relapsed/refractory large B-cell lymphoma and the ongoing ...

for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric ...